The efficacy and safety of Apixaban versus warfarin are preserved in patients with atrial fibrillation and extremely high body weight: insights from the Aristotle study
M Fudim, R Lopes, J Alexander, D Wojdyla… - Journal of the American …, 2018 - jacc.org
Background Recent guidelines caution against the use of non-vitamin K antagonists oral
anticoagulants (NOACs) in patients with extremely high body weight (≥ 120 kg) due to lack …
anticoagulants (NOACs) in patients with extremely high body weight (≥ 120 kg) due to lack …
Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight: insights from the ARISTOTLE trial
SH Hohnloser, M Fudim, JH Alexander, DM Wojdyla… - Circulation, 2019 - Am Heart Assoc
Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
Relationship between body weight and pharmacokinetics of apixaban in patients with atrial fibrillation: insights from the ARISTOTLE trial
J Harrington, A Giczewska, D Wojdyla, JB Washam… - Circulation, 2021 - Am Heart Assoc
Introduction: Apixaban dosing in atrial fibrillation (AF) is 5 mg BID or 2.5 mg BID in patients
with≥ 2 dose-reduction criteria: age> 80 years, weight< 60 kg, or creatinine> 1.5 mg/dl …
with≥ 2 dose-reduction criteria: age> 80 years, weight< 60 kg, or creatinine> 1.5 mg/dl …
Short-term outcomes of apixaban versus warfarin in patients with atrial fibrillation: Is body weight an important consideration?
GYH Lip, AA Khan, B Olshansky - Circulation, 2019 - Am Heart Assoc
Atrial fibrillation (AF) is associated with increased risk of stroke and mortality. Prevention of
thromboembolism is the foundation of managing this common disease. 1 The nonvitamin K …
thromboembolism is the foundation of managing this common disease. 1 The nonvitamin K …
Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation
D DeCamillo, B Haymart, X Kong, S Kaatz… - Journal of thrombosis …, 2023 - Springer
Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …
ADVERSE EVENTS IN LOW VERSUS NORMAL BODY WEIGHT PATIENTS PRESCRIBED APIXABAN OR RIVAROXABAN FOR ATRIAL FIBRILLATION
D DeCamillo, B Haymart, X Kong, S Kaatz, M Ali… - 2023 - scholarlycommons.henryford.com
Background: Clinical trials comparing direct oral anticoagulants (DOACs) to warfarin
included only a small number of patients that weighed less than 60 kilograms (kg). The …
included only a small number of patients that weighed less than 60 kilograms (kg). The …
Body mass index and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the aristotle (apixaban for reduction in stroke and other …
RK Sandhu, J Ezekowitz, U Andersson… - Journal of the American …, 2015 - jacc.org
Background: Body Mass Index (BMI) is a risk factor for atrial fibrillation (AF). Few studies
have examined the relations between BMI and outcomes in patients with AF treated with …
have examined the relations between BMI and outcomes in patients with AF treated with …
Association of low body weight with clinical outcomes in elderly atrial fibrillation patients receiving apixaban—J-ELD AF registry subanalysis
T Kadosaka, T Nagai, S Suzuki, I Sakuma… - … Drugs and Therapy, 2022 - Springer
Purpose Although direct oral anticoagulants are effective and safe in preventing stroke in
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …
Non-vitamin K antagonist oral anticoagulant for atrial fibrillation in obese patients
SY Wang, RP Giugliano - The American Journal of Cardiology, 2020 - Elsevier
Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …
相关搜索
- body weight atrial fibrillation
- warfarin in patients atrial fibrillation
- body weight safety of apixaban
- body weight warfarin in patients
- safety of apixaban atrial fibrillation
- adverse events atrial fibrillation
- reduction in stroke atrial fibrillation
- body weight clinical outcomes
- safety of apixaban warfarin in patients
- safety of apixaban veteran affairs
- warfarin in patients important consideration
- obese patients effectiveness and safety
- body weight registry subanalysis
- body weight important consideration
- important consideration atrial fibrillation
- body weight efficacy and safety